New drug shows promise for NF1 skin tumors in early trial
NCT ID NCT06159166
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called mirdametinib in adults with neurofibromatosis type 1 (NF1) who have skin tumors called cutaneous neurofibromas. The goal is to find a safe dose and see if the drug can shrink these tumors. About 24 people will take the drug daily or on a three-week-on, one-week-off schedule at Johns Hopkins University.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS NEUROFIBROMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a two-drug combo better tame prostate trouble?
- Could a cholesterol drug boost reading skills in kids with NF1?
- New hope for kids with resistant tumors: drug combo enters safety trial
- New gel could shrink neurofibroma tumors without surgery
- New antibiotic shows promise against Drug-Resistant lung bug
- New drug cocktail takes on rare nerve tumors